These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1947 related articles for article (PubMed ID: 8823492)
1. In vivo antitumor activity of S 16020-2, a new olivacine derivative. Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug. Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972 [TBL] [Abstract][Full Text] [Related]
3. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice. Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152). Fujimoto K; Oka T; Morimoto M Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218 [TBL] [Abstract][Full Text] [Related]
6. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Kobayashi M; Natsume T; Tamaoki S; Watanabe J; Asano H; Mikami T; Miyasaka K; Miyazaki K; Gondo M; Sakakibara K; Tsukagoshi S Jpn J Cancer Res; 1997 Mar; 88(3):316-27. PubMed ID: 9140117 [TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363. Pierré A; Kraus-Berthier L; Atassi G; Cros S; Poupon MF; Lavielle G; Berlion M; Bizzari JP Cancer Res; 1991 May; 51(9):2312-8. PubMed ID: 2015595 [TBL] [Abstract][Full Text] [Related]
9. In vitro cytotoxicity of S16020-2, a new olivacine derivative. Léonce S; Perez V; Casabianca-Pignede MR; Anstett M; Bisagni E; Pierré A; Atassi G Invest New Drugs; 1996; 14(2):169-80. PubMed ID: 8913838 [TBL] [Abstract][Full Text] [Related]
10. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice. Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251 [TBL] [Abstract][Full Text] [Related]
12. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide. Burres NS; Clement JJ Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice. Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803 [TBL] [Abstract][Full Text] [Related]
15. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Kruczynski A; Colpaert F; Tarayre JP; Mouillard P; Fahy J; Hill BT Cancer Chemother Pharmacol; 1998; 41(6):437-47. PubMed ID: 9554586 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C. Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076 [TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of bizelesin in mice. Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280 [TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of S 16020-2 in two orthotopic models of lung cancer. Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Pierré A; Atassi G Anticancer Drugs; 1997 Mar; 8(3):276-82. PubMed ID: 9095333 [TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334 [TBL] [Abstract][Full Text] [Related]
20. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent. Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]